Conformational Changes of G Protein-Coupled Receptors During Their Activation by Agonist Binding

Journal of Receptors and Signal Transduction

Volumn 23, Issue 2-3, 2003, Pages 123-153

  Bissantz, Caterina ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Bovine rhodopsin; Conformational changes; GPCR; Homology model; Receptor activation; Structure based drug design

Indexed keywords

11 CIS RETINAL; 4 AMINOBUTYRIC ACID RECEPTOR; ADENOSINE A1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BRADYKININ B2 RECEPTOR; DELTA OPIATE RECEPTOR; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR KINASE; GONADORELIN RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE DIPHOSPHATE; GUANOSINE TRIPHOSPHATE; KAPPA OPIATE RECEPTOR; LIGAND; MEMBRANE PROTEIN; METABOTROPIC RECEPTOR; MU OPIATE RECEPTOR; PARATHYROID HORMONE RECEPTOR; PROTIRELIN RECEPTOR; RETINAL; RHODOPSIN; SIGMA OPIATE RECEPTOR; SOMATOSTATIN RECEPTOR;

AGONIST; BINDING KINETICS; CONFORMATIONAL TRANSITION; DIMERIZATION; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HUMAN; HYDROGEN BOND; ISOMERISM; LIGAND BINDING; NONHUMAN; PALMITOYLATION; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; X RAY ANALYSIS;

ANIMALS; BINDING SITES; DIMERIZATION; DRUG DESIGN; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN FOLDING; RECEPTORS, G-PROTEIN-COUPLED; RHODOPSIN;

BOVINAE;

EID: 0242362716     PISSN: 10799893     EISSN: 15324281     Source Type: Journal    
DOI: 10.1081/RRS-120025192     Document Type: Review

References (129)

1. Flower DR. Modelling G-protein-coupled receptors for drug design. Biochim Biophys Acta 1999; 1422(3):207-234.
2. Schwartz TW. Locating ligand-binding sites in 7TM receptors by protein engineering. Curr Opin Biotech 1994; 5(4):434-444.
3. Franke RR, Konig B, Sakmar TP, Khorana HG, Hofmann KP. Rhodopsin mutants that bind but fail to activate transducin. Science 1990; 250(4977):123-125.
4. Franke RR, Sakmar TP, Graham RM, Khorana HG. Structure and function in rhodopsin. J Biol Chem 1992; 267(21):14767-14774.
5. Marin EP, Krishna AG, Zvyaga TA, Isele J, Siebert F, Sakmar TP. The amino terminus of the fourth cytoplasmic loop of rhodopsin modulates rhodopsin-transducin interaction. J Biol Chem 2000; 275(3):1930-1936.
6. Ernst OP, Meyer CK, Marin EP, Henklein P, Fu WY, Sakmar TP, Hofmann KP. Mutation of the fourth cytoplasmic loop of rhodopsin affects binding of transducin and peptides derived from the carboxyl-terminal sequences of transducin α and γ subunits. J Biol Chem 2000; 275(3):1937-1943.
7. Hamm H. The many faces of G protein signaling. J Biol Chem 1998; 273(2):669-672.
8. Lefkowitz RJ. G Protein-coupled receptors III. New roles for receptor kinases and β-arrestins in receptor signaling and desensitization. J Biol Chem 1998; 273(30):18677-18680.
9. 2-adrenergic receptor-Src protein kinase complexes. Science 1999; 283(5402):655-661.
10. + exchange. Nature 1998; 392(6676):626-630.
11. Brakeman P, Lanahan AA, O'Brien R, Roche K, Barnes CA, Huganir RL, Worley PF. Homer: a protein that selectively binds metabotropic glutamate receptors. Nature 1997; 386(6622):284-288.
12. Lefkowitz RJ, Pitcher J, Krueger K, Daaka Y. Mechanisms of β-adrenergic receptor desensitization and resensitization. Adv Pharmacol 1998; 42:416-420.
13. Horn F, Weare J, Beukers MW, Hörsch S, Bairoch A, Chen W, Edvardsen Ø, Campagne F, Vriend G. GPCRDB: an information system for G protein-coupled receptors. Nucleic Acids Res 1998; 26(1):277-281.
14. Ji TH, Grossmann M, Ji I. G protein-coupled receptors I. Diversity of receptor-ligand interactions. J Biol Chem 1998; 273(28):17299-17302.
15. Henderson R, Baldwin JM, Ceska TA, Zemlin F, Beckmann E, Downing KH. Model for the structure of bacteriorhodopsin based on high-resolution electron cryomicroscopy. J Mol Biol 1990; 213(4):899-929.
16. Hibert MF, Trumpp-Kallmeyer S, Bruinvels A, Hoflack J. Three-dimensional models of neurotransmitter G-binding protein-coupled receptors. Mol Pharmacol 1991; 40(1):8-15.
17. Baldwin JM. The probable arrangement of the helices in G protein-coupled receptors. EMBO J 1993; 12(4):1693-1703.
18. Schertler GFX, Villa C, Henderson R. Projection structure of rhodopsin. Nature 1993; 362(6422):770-772.
19. Unger VM, Hargrave PA, Baldwin JM, Schertler GFX. Arrangement of rhodopsin transmembrane alpha helices obtained by electron cryo-microscopy. Nature 1997; 389(6647):203-206.
20. Baldwin JM, Schertler GFX, Unger VM. An alpha-carbon template for the transmembrane helices in the rhodopsin family of G-protein-coupled receptors. J Mol Biol 1997; 272(1):144-164.
21. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le Trong I, Teller DC, Okada T, Stenkamk RE, Yamamoto M, Miyano M. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 2000; 289(5480):739-745.
22. Teller DC, Okada T, Behnke CA, Palczewski K, Stenkamp RE. Advances in determination of a high-resolution three-dimensional structure of rhodopsin, a model of G-protein-coupled receptors (GPCRs). Biochemistry 2001; 40(26): 7761-7772.
23. Okada T, Fujiyoshi Y, Silow M, Navarro J, Landau EM, Shichida Y. Functional role of internal water in rhodopsin revealed by x-ray crystallography. Proc Natl Acad Sci USA 2002; 99(9):5982-5987.
24. Singh D, Hudson BS, Middleton C, Birge RR. Conformation and orientation of the retinyl chromophore in rhodopsin: a critical evaluation of recent NMR data on the basis of theoretical calculation results in a minimum energy consistent with all experimental data. Biochemistry 2001; 40(14):4201-4204.
25. Fotiadis D, Liang Y, Filipek S, Saperstein DA, Engel A, Palczewski K. Rhodopsin dimers in native disc membranes. Nature 2003; 421(6919):127-128.
26. Borhan B, Souto ML, Imai H, Shichida Y, Nakanishi K. Movement of retinal along the visual transduction path. Science 2000; 288(5474):2209-2212.
27. Jäger F, Fahmy K, Sakmar TP, Siebert F. Identification of glutamic acid 113 as the Schiff base proton acceptor in the metarhodopsin II photointermediate of rhodopsin. Biochemistry 1994; 33(36):10878-10882.
28. Arnis S, Fahmy K, Hofmann KP, Sakmar TP. A conserved carboxylic acid group mediates light-dependent proton uptake and signaling by rhodopsin. J Biol Chem 1994; 269(39):23879-23881.
29. Arnis S, Hofmann KP. Two different forms of metarhodopsin II: Schiff base deprotonation precedes proton uptake and signaling state. Proc Natl Acad Sci USA 1993; 90(16):7849-7853.
30. Meyer CK, Böhme M, Ockenfels A, Gärtner W, Hofmann KP, Ernst O. Signaling states of rhodopsin. J Biol Chem 2000; 275(26):19713-19718.
31. Jang G, Kuksa V, Filipek S, Bartl F, Ritter E, Gelb MH, Hofmann KP, Palczewski K. Mechanism of rhodopsin activation as examined with ring-constrained retinal analogs and the crystal structure of the ground state protein. J Biol Chem 2001; 276(28):26148-26153.
32. Kuksa V, Bartl F, Maeda T, Jang G, Ritter E, Heck M, Van Hooser JP, Liang Y, Filipek S, Gelb MH, Hofmann KP, Palczewski K. Biochemical and physiological properties of rhodopsin regenerated with 11-cis-6-ring- and 7-ring-retinals. J Biol Chem 2002; 277(44):42315-42324.
33. Lin SW, Sakmar TP. Specific tryptophan UV-absorbance changes are probes of the transition of rhodopsin to its active state. Biochemistry 1996; 35(34):11149-11159.
34. Altenbach C, Klein-Seetharaman J, Hwa J, Khorana HG, Hubbell WL. Structural features and light-dependent changes in the sequence 59-75 connecting helices I and II in rhodopsin: a site-directed spin-labeling study. Biochemistry 1999; 38(25):7945-7949.
35. Farahbakhsh ZT, Ridge KD, Khorana HG, Hubbell WL. Mapping light-dependent structural changes in the cytoplasmic loop connecting helices C and D in rhodopsin: a site-directed spin-labeling study. Biochemistry 1995; 34(27):8812-8819.
36. Altenbach C, Yang K, Farmes DL, Farahbakhsh ZT, Khorana HG, Hubbell WL. Structural features and light-dependent changes in the cytoplasmic interhelical E-F loop region of rhodopsin: a site-directed spin-labeling study. Biochemistry 1996; 35(38):12470-12478.
37. Farrens DL, Altenbach C, Yang K, Hubbell WL, Khorana HG. Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin. Science 1996; 274(5288):768-770.
38. Dunham TD, Farrens DL. Conformational changes in rhodopsin. J Biol Chem 1999; 274(3):1683-1690.
39. Cai K, Klein-Seetharaman J, Hwa J, Hubbell WL, Khorana HG. Structure and function in rhodopsin: effects of disulfide cross-links in the cytoplasmic face of rhodopsin on transducins activation and phosphorylation by rhodopsin kinase. Biochemistry 1999; 38(39):12893-12898.
40. Sheikh SP, Zvyaga TA, Lichtarge TP, Sakmar P, Bourne HR. Rhodopsin activation blocked by metal-ion-binding sites linking transmembrane helices C and F. Nature 1996; 383(6598):347-350.
41. Altenbach C, Cai K, Klein-Seetharaman J, Khorana HG, Hubbell WL. Structure and function in rhodopsin: mapping light-dependent changes in distance between residue 65 in helix TM1 and residues in the sequence 306-319 at the cytoplasmic end of helix TM7 and in helix H8. Biochemistry 2001; 40(51):15483-15492.
42. Altenbach C, Klein-Seetharaman J, Cai K, Khorana HG, Hubbell WL. Structure and function in rhodopsin: mapping light-dependent changes in distance between residue 316 in helix 8 and residues in the sequence 60-75, covering the cytoplasmic end of helices TM1 and TM2 and their connection loop CL1. Biochemistry 2001; 40(51):15493-15500.
43. Abdulaev N, Ridge KD. Light induced exposure of the cytoplasmic end of transmembrane helix seven in rhodopsin. Proc Natl Acad Sci USA 1998; 95(22):12854-12859.
44. Krishna AG, Menon ST, Terry TJ, Sakmar TP. Evidence that helix 8 of rhodopsin acts as a membrane-dependent conformational switch. Biochemistry 2002; 41(26): 8298-8309.
45. 2-adrenergic receptor. J Biol Chem 1995; 270(47):28268-28275.
46. 2-adrenoceptor. EMBO J 1997; 16(22):6737-6747.
47. 2-adrenergic receptor mapped by site-selective fluorescent labeling. J Biol Chem 2001; 276(12):9279-9290.
48. 2 adrenergic receptor. Proc Natl Acad Sci USA 2001; 98(11):5997-6002.
49. 2-adrenoceptor and the parathyroid hormone receptor. J Biol Chem 1999; 274(24):17033-17041.
50. 3 muscarinic acetylcholine receptor activation probed by the use of an in situ disulfide cross-linking strategy. J Biol Chem 2002; 277(3):2247-2257.
51. Struthers M, Yu H, Kono M, Oprian DD. Tertiary interactions between the fifth and sixth transmembrane segments of rhodopsin. Biochemistry 1999; 38(20):6597-6603.
52. Struthers M, Yu H, Oprian DD. G protein-coupled receptor activation: analysis of a highly constrained, "straitjacketed" rhodopsin. Biochemistry 2000; 39(27):7938-7942.
53. Cohen GB, Yang T, Robinson PR, Oprian DD. Constitutive activation of opsin: influence of charge at position 134 and size at position 296. Biochemistry 1993; 32(23):6111-6115.
54. 2 adrenergic receptor: constitutive activity, structural instability, and conformational rearrangement of transmembrane segment 6. Mol Pharmacol 1999; 56(1):175-184.
55. Alewijnse AE, Timmerman H, Jacobs EH, Smit MJ, Roovers E, Cotecchia S, Leurs R. The effect of mutations in the DRY motif on the constitutive activity and structural instability of the histamine H2 receptor. Mol Pharmacol 2000; 57(5):890-898.
56. Scheer A, Fanelli F, Costa T, De Benedetti PG, Cotecchia S. The activation process of the α1B-adrenergic receptor: potential role of protonation and hydrophobicity of a highly conserved aspartate. Proc Natl Acad Sci USA 1997; 94(3):808-813.
57. Gether U, Ballesteros JA, Seifert R, Sanders-Bush E, Weinstein H, Kobilka BK. Structural instability of a constitutively active G protein-coupled receptor. J Biol Chem 1997; 272(5):2587-2590.
58. Kim J, Altenbach C, Thurmond RL, Khorana HG, Hubbell WL. Structure and function in rhodopsin: rhodopsin mutants with a neutral amino acid at E134 have a partially activated conformation in the dark state. Proc Natl Acad Sci USA 1997; 94(26):14273-14278.
59. 2 adrenoceptor function. J Biol Chem 2000; 275(5):3121-3127.
60. Ballesteros J, Kitanovic S, Guarnieri F, Davies P, Fromme BJ, Konvicka K, Chi L, Millar RP, Davidson JS, Weinstein H, Sealfon SC. Functional microdomain in G-protein-coupled receptors. J Biol Chem 1998; 273(17):10445-10453.
61. 2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6. J Biol Chem 2001; 276(31):29171-29177.
62. Greasley PJ, Fanelli F, Rossier O, Abuin L, Cotecchia, S. Mutategensis and modeling of the α1B-adrenergic receptor highlight the role of the helix 3/helix 6 interface in receptor activation. Mol Pharmacol 2002; 61(5):1025-1032.
63. Shapiro DA, Kristiansen K, Weiner DM, Kroeze WK, Roth BL. Evidence for a model of agonist-induced activation of 5-hydroxytryptamine 2A serotonin receptors that involve the disruption of a strong ionic interaction between helices 3 and 6. J Biol Chem 2002; 277(13):11441-11449.
64. Huang P, Li J, Chen C, Visiers I, Weinstein H, Liu-Chen LY. Functional role of a conserved motif in TM6 of the rat μ opioid receptor: constitutively active and inactive receptors result from substitutions of Thr6.34(279) with Lys and Asp. Biochemistry 2001; 40(45):13501-13509.
65. Huang P, Visiers I, Liu-Chen LY. The local environment at the cytoplasmic end of TM6 of the μ opioid receptor differs from those of rhodopsin and monoamine receptors: introduction of an ionic lock between the cytoplasmic ends of helices 3 and 6 by a L6.30(275)E mutation inactivates the μ opioid receptor and reduces constitutive activity of its T6.34(279)K mutant. Biochemistry 2002; 41(40):11972-11980.
66. Robinson PR, Cohen GB, Zhukovsky EA, Oprian DD. Constitutively actively mutants of rhodopsin. Neuron 1992; 9(4):719-725.
67. Befort K, Zilliox C, Fillio D, Yue S, Kieffer BL. Constitutive activation of the μ opioid receptor by mutations in transmembrane domains III and VII. J Biol Chem 1999; 274(26):18574-18581.
68. Porter JE, Hwa J, Perez DM. Activation of the α1B-adrenergic receptor is initiated by disruption of an interhelical salt bridge constraint. J Biol Chem 1996; 271(45): 28318-28323.
69. 1a angiotensin II receptor induces its constitutive activation. J Biol Chem 1997; 272(3):1822-1826.
70. Han M, Smith SO, Sakmar TP. Constitutive activation of opsin by mutation of methionine 257 on transmembrane helix 6. Biochemistry 1998; 37(22):8253-8261.
71. Fritze O, Filipek S, Kuksa V, Palczewski K, Hofmann KP, Ernst OP. Role of the conserved NPxxY(x)5,6F motif in the rhodopsin ground state and during activation. Proc Natl Acad Sci USA 2003; 100(5):2290-2295.
72. Zhou W, Flanagan C, Ballesteros JA, Konvicka K, Davidson JS, Weinstein H, Millar RP, Sealfon SC. A reciprocal mutation supports helix 2 and 7 proximity in the gonatropin-releasing hormone receptor. Mol Pharmacol 1994; 45(2):165-170.
73. 2A receptor. J Biol Chem 1995; 270(28):16683-16688.
74. Perlman JH, Colson AO, Wang W, Bence K, Osman R, Gershengorn MC. Interactions between conserved residues in transmembrane helices 1, 2 and 7 of the thyrotropin-releasing hormone receptor. J Biol Chem 1997; 272(18):11937-11942.
75. 2 receptor: functional roles and structural implications. Biochem J 1999; 339(PT1):55-61.
76. Munshi UM, Pogozheva ID, Menon KMJ. Highly conserved serine in the third transmembrane helix of the luteinizing hormone/human chorionic gonadotropin receptor regulates receptor activation. Biochemistry 2003; 42(13):3708-3715.
77. 2-adrenergic receptor activation. J Biol Chem 2002; 277(43):40989-40996.
78. Ebersole BJ, Visiers I, Weinstein H, Sealfon SC. Molecular basis of partial agonism: orientation of indoleamine ligands in the binding pocket of the human serotonin 5-HT2A receptor determines relative efficacy. Mol Pharmacol 2003; 63(1):36-43.
79. Farahbakhsh ZT, Hideg K, Hubbell WL. Photoactivated conformational changes in rhodopsin: a time-resolved spin label study. Science 1993; 262(5138):1416-1419.
80. Heck M, Schädel SA, Maretzki D, Bartl FJ, Ritter E, Palczewski K, Hofmann KP. Signaling states of rhodopsin. J Biol Chem 2003; 278(5):3162-3169.
81. Gether U, Kobilka BK. G protein-coupled receptors II. Mechanism of agonist activation. J Biol Chem 1998; 273(29):17979-17982.
82. Peleg G, Ghanouni P, Kobilka BK, Zare RN. Single-molecule spectroscopy of the β2 adrenergic receptor: observation of conformational substates in a membrane protein. Proc Natl Acad Sci USA 2001; 98(15):8469-8474.
83. 2 adrenergic receptor. J Biol Chem 2001; 276(27):24433-24436.
84. Rios CD, Jordan BA, Gomes I, Devi LA. G-protein-coupled receptor dimerization: modulation of receptor function. Pharmacol Therapeut 2001; 92(2-3):71-87.
85. Angers S, Salahpour A, Bouvier M. Dimerization: an emerging concept for G protein-coupled receptor ontogeny and function. Annu Rev Pharmacol Toxicol 2002; 42:409-435.
86. Ng GY, O'Dowd BF, Lee SP, Chung HT, Brann MR, Seeman P, George SR. Dopamine D2 receptor dimers and receptor-blocking peptides. Biochem Biophys Res Commun 1996; 227:200-204.
87. Romano S, Yang WL, O'Malley KL. Metobotropic glutamate receptor 5 is a disulfide-linker dimer. J Biol Chem 1996; 271(45):28612-28616.
88. Cvejic S, Devi LA. Dimerization of the δ opioid receptor: implication for a role in receptor internalization. J Biol Chem 1997; 272(43):26959-26964.
89. McVey M, Kellet E, Rees S, Wilson S, Pope AJ, Milligan G. Monitoring receptor oligomerization using time-resolved fluorescence resonance energy transfer and bioluminescence resonance energy transfer: the human δ-opioid receptor displays constitutive oligomerization at the cell surface which is not regulated by receptor occupancy. J Biol Chem 2001; 276(17):14092-14099.
90. Bai M, Trivedi S, Brown EM. Dimerization of the extracellular calcium-sensing receptor (CaR) on the cell surface of caR-transfected HEK293 cells. J Biol Chem 1998; 273(36):23605-23610.
91. Zeng FY, Wess J. Identification and molecular characterization of m3 muscarinic receptor dimers. J Biol Chem 1999; 274(27):19487-19497.
92. Angers S, Salahpour A, Joly E, Hilairet S, Chelsky D, Dennis M, Bouvier M. Detection of β2-adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET). Proc Natl Acad Sci USA 2000; 97(7):3684-3689.
93. Hebert TE, Moffett S, Morello JP, Loisel TP, Bichet DG, Barret C, Bouvier M. A peptide derived from a β2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation. J Biol Chem 1996; 271(27):16384-16392.
94. Kroeger KM, Hanyaloglu AC, Seeber RM, Miles L, Eidne KA. Constitutive and agonist-dependent homooligomerization of the thyrotropin-releasing hormone receptor; detection in living cells using bioluminescence resonance energy transfer. J Biol Chem 2001; 276(16):12736-12743.
95. Cornea A, Janovick JA, Maya-Nunez G, Conn PM. Gonadotropin releasing hormone microaggregation: rate monitored by fluorescence resonance energy transfer. J Biol Chem 2001; 276(3):2153-2158.
96. Horvat RD, Roess DA, Nelson SE, Barisas BG, Clay CM. Binding of agonist but not antagonist leads to fluorescence resonance energy transfer between intrinsically fluorescent gonadotropin releasing hormone receptors. Mol Endocrinol 2001; 15(5):695-703.
97. White JH, Wise A, Main MJ, Green A, Fraser NJ, Disney GH, Barnes AA, Emson P, Foord SM, Marshall FH. Heterodimerization is required for the formation of a functional GABA(B) receptor. Nature 1998; 396(6712):679-682.
98. Jones KA, Borowsky B, Tamm JA, Craig DA, Durkin MM, Dai M, Yao WJ, Johnson M, Gunwaldsen C, Huang LY, Tang C, Shen Q, Salon JA, Morse K, Laz T, Smith KE, Nagarathnam D, Noble SA, Branchek TA, Gerald C. GABA(B) receptors function as a heteromeric assembly of the subunits GABA(B)R1 and GABA(B)R2. Nature 1998; 396(6712):674-679.
99. Kaupmann K, Malitschek B, Schuler V, Heid J, Froestl W, Beck P, Mosbacher J, Bischoff S, Kulik A, Shigemoto R, Karschin A, Bettler B. GABA(B) receptor subtypes assemble into functional heteromeric complexes. Nature 1998; 396(6712):683-687.
100. Kuner R, Kohr G, Grunewald S, Eisenhardt G, Bach A, Kornau HC. Role of heteromer formation in GABAB receptor function. Science 1999; 283(5398):74-77.
101. Jordan BA, Devi LA. G-protein-coupled receptor heterodimerization modulates receptor function. Nature 1999; 399(6737):697-700.
102. Gomes I, Jordan BA, Gupta A, Trapaidze N, Nagy V, Devi LA. Heterodimerization of μ and δ opioid receptors: a role in opiate synergy. J Neurosci 2000; 20(22):RC110.
103. Pfeiffer M, Koch T, Schroder H, Klutzny M, Kirscht S, Kreienkamp HJ, Höllt V, Schulz S. Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst3 receptor function by heterodimerization with sst2A. J Biol Chem 2001; 276(17):14027-14036.
104. Gines S, Hillion J, Torvinen M, Le Crom S, Casado V, Canela EI, Rondin S, Lew JY, Watson S, Zoli M, Agnati LF, Vernierá P, Luis C, Ferré S, Fuxe K, Franco R. Dopamine D1 and adenosine A1 receptors form functionally interacting heteromeric complexes. Proc Natl Acad Sci USA 2000; 97(15):8606-8611.
105. Abdalla S, Lother H, Quitterer U. AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. Nature 2000; 407(6800):94-98.
106. Jordan BA, Trapaidze N, Gomes I, Nivarthi R, Devi LA. Oligomerization of opioid receptors with beta 2-adrenergic receptors: a role in trafficking and mitogen-activated protein kinase activation. Proc Natl Acad Sci USA 2001; 98(1):343-348.
107. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 2000; 288(5463):154-157.
108. Kunishima N, Shimada Y, Tsuji Y, Sato T, Yamamoto M, Kumasaka T, Nakanishi S, Jingami H, Morokawa K. Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. Nature 2000; 407(6807):971-977.
109. B heterodimer as the functional receptor. J Pharmacol Exp Ther 2000; 293(2):460-467.
110. Klabunde T, Hessler G. Drug design strategies for targeting G-protein-coupled receptors. Chem Bio Chem 2002; 3(10):928-944.
111. Visiers I, Ballesteros JA, Weinstein H. Three-dimensional representations of G protein-coupled receptor structures and mechanisms. Methods Enzymol 2002; 343:329-371.
112. Shacham S, Topf M, Avisar N, Glaser F, Marantz Y, Bar-Haim S, Noiman S, Naor Z, Becker OM. Modeling the 3D structure of GPCRs from sequence. Med Res Rev 2001; 21(5):472-483.
113. Vaidehi N, Floriano WB, Trabanino R, Hall SE, Freddolino P, Choi EJ, Zamanakos G, Goddard III WA. Prediction of structure and function of G protein-coupled receptors. Proc Natl Acad Sci USA 2002; 99(20):12622-12627.
114. Hibert MF, Trumpp-Kallmeyer S, Bruinvels A, Hoflack J. Three-dimensional models of neurotransmitter G-binding protein-coupled receptors. Mol Pharmacol 1991; 40(1):8-15.
115. Trumpp-Kallmeyer S, Hoflack J, Bruinvels A, Hibert M. Modeling of G-protein-coupled receptors: application to dopamine, adrenaline, serotonin, acetylcholine, and mammalian opsin receptors. J Med Chem 1992; 35(19):3448-3462.
116. Cho W, Taylor LP, Mansour A, Akil H. Hydrophobic residues of the D2 dopamine receptor are important for binding and signal transduction. J Neurochem 1995; 65(5):2105-2115.
117. Matsui H, Lazerno S, Birdsall NJM. Probing the location of the allosteric site on m1 muscarinic receptors by site-directed mutagenesis. Mol Pharmacol 1995; 47(1):88-98.
118. Bourdon H, Trumpp-Kallmeyer S, Schreuder H, Hoflack J, Hibert M, Wermuth CG. Modelling of the binding site of the human m1 muscarinic receptor: experimental validation and refinement. J Comp-Aided Mol Des 1997; 11(14):317-332.
119. Choudary MS, Sachs N, Uluer RA, Glennon RB, Westkaemper RB, Roth BL. Different ergoline and ergopeptine binding to 5-HT2a receptors: ergolines require an aromatic residue at position 340 for high affinity binding. Mol Pharmacol 1995; 47(3):450-457.
120. Roth BL, Shoham M, Choudary MS, Khan N. Identification of conserved aromatic residues essential for agonist binding and second messenger production at 5-hydroxytryptamine 2a receptors. Mol Pharmacol 1997; 52(2):259-266.
121. Ballesteros JA, Shi L, Javitch JA. Structural mimicry in G protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors. Mol Pharmacol 2001; 60(1):1-19.
122. Mouillac B, Chini B, Balestre MN, Elands J, Trumpp-Kallmeyer S, Hoflack J, Hibert M, Jard S, Barberis C. The binding site of neuropeptide vasopressin V1a receptor. J Biol Chem 1995; 270(43):25771-25777.
123. Chini B, Mouillac B, Ala Y, Balestre MN, Trumpp-Kallmeyer S, Hoflack J, Elands J, Hibert M, Manning M, Jard S, Barberis C. EMBO J 1995; 14(10):2176-2182.
124. Cotte N, Balestre MN, Aumelas A, Mahé E, Phalipou S, Morin D, Hibert M, Manning M, Durroux T, Barberis C, Mouillac B. Conserved aromatic residues in the transmembrane region VI of the V1a vasopressin receptor differentiate agonist vs. antagonist ligand binding. Eur J Biochem 2000; 267(13):4253-4263.
125. Stenkamp RE, Filipek S, Driessen CAGG, Teller DC, Palczewski K. Crystal structure of rhodopsin: a template for cone visual pigments and other G protein-coupled receptors. Biochim Biophys Acta 2002; 1565(2):168-182.
126. Bissantz C, Bernard P, Hibert M, Rognan D. Protein-based virtual screening of chemical databases. 2. Are homology models of G-protein coupled receptors suitable targets? Proteins 2003; 50(1):5-25.
127. Bissantz C, Folkers G, Rognan D. Protein-based virtual screening of chemical databases. 1. Evaluation of different docking/scoring combinations. J Med Chem 2000; 43(25):4759-4767.
128. 2C/2B receptor antagonists. J Med Chem 1996; 39(25):4966-4977.
129. 2C/2B receptor antagonists as potential anxiolytic agents: synthesis, quantitative structure-activity relationships, and molecular modeling of substituted 1-(3-pyridylcarbamoyl)indolines. J Med Chem 1998; 41(10):1598-1612.